Delivery Order SPE2DB24D1201-SPE2DB25FJEDN
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a specialty pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $11,500.66, is scheduled for completion by August 14, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of HUMIRA(CF) Pen 40 mg/0.4 mls, a pharmaceutical product used for treating autoimmune conditions. This firm fixed-price delivery order, valued at $1,132.95, represents a non-set-aside competitive award with an ultimate completion date of September 4, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Humira (cf) Pen 40 mg/0.4 mls, a pharmaceutical product used primarily for the treatment of inflammatory conditions. This firm fixed price delivery order, valued at $1,510.60, represents a non-set-aside competitive award with an ultimate completion date of August 13, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA(CF) Pen 80 mg/0.8 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed price delivery order, valued at $1,453.31, represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The award was made through open competition with no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used to treat autoimmune conditions. This competitively awarded, firm fixed-price delivery order has a ceiling value of $2,265.90 and is set to complete by August 13, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside award, this...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product used in treating autoimmune conditions. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,156.39 and is scheduled for completion by September 5, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $71,310.77 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a brand-name pharmaceutical product used in the treatment of inflammatory conditions. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $9,166.56 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price contract, awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, represents a non-competed delivery order under AmerisourceBergen's existing DLA contract vehicle. The place of performance is listed as the company's corporate office in...
- The Defense Logistics Agency awarded a $5,506.33 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price contract, which is set to be completed by August 21, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The delivery will be performed at the contractor's corporate...
- The Defense Logistics Agency awarded a $2,265.90 delivery order to AmerisourceBergen Drug Corp for HUMIRA Pen 40 MG/0.8 MLS, a pharmaceutical product used in the treatment of autoimmune conditions. This contract, awarded on August 19, 2025, represents a firm fixed price delivery order with an ultimate completion date of August 20, 2025. The award was made through open competition with no set-aside designation, and the product will be delivered to AmerisourceBergen's corporate office location...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJEDNDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $10,098.59, represents a competitive award with no set-aside designation and is scheduled for completion by September 11, 2025. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's prime indefinite delivery contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying brand-name and generic medications, vaccines, and specialized healthcare commodities to military and veteran healthcare systems. The company's extensive portfolio of federal contract awards demonstrates its capability to meet diverse pharmaceutical supply requirements across multiple therapeutic domains through open and competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.1k | 9/10/25 |